Mary Anti Chama
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Mary Anti Chama has a total of 86 co-authors. Here are the top co-authors by number of shared publications:
Beverly Egyir
Department of Bacteriology, Noguchi Memorial Institute for Medical Research, University of Ghana, Accra, Ghana
3 shared publications- Dorcas Osei-Safo
Department of Chemistry, School of Physical and Mathematical Sciences, College of Basic and Applied Sciences, University of Ghana, Legon, Accra P.O. Box LG 56, Ghana
3 shared publications Andreas Bender
Yusuf Hamied Department of Chemistry, University of Cambridge, United Kingdom
2 shared publicationsDorcas Osei-Safo
Department of Chemistry, SPMS, CBAS, University of Ghana, Ghana
2 shared publicationsIvan Addae-Mensah
Department of Chemistry, School of Physical and Mathematical Sciences, P.O Box LG 56, University of Ghana, Legon, Ghana
2 shared publicationsJessica Asomaniwaa Armah
Department of Chemistry, School of Physical and Mathematical Sciences, University of Ghana, Legon, Accra, Ghana
2 shared publications
Latest Publications
- Open Access
- 24 August 2026
- Published by Springer Nature in Journal of Cheminformatics
- Vol. 18 (1) , 122
Computational applications in secondary metabolite discovery (CAiSMD) 2026: focus on secondary metabolites towards drug discovery
- 24 August 2026
- Published by Springer Nature in Journal of Cheminformatics
- Vol. 18 (1) , 122
Open AccessComputational applications in secondary metabolite discovery (CAiSMD) 2026: focus on secondary metabolites towards drug discovery
- Open Access
Therapeutic Potential of Dichapetalin M in Metastatic and ER-positive Breast Cancer: Evidence from Cell Line Studies
Background: Dichapetalin M (Dic M), an active compound extracted from medicinal plants in the Dichapetalum genus, has been previously shown to possess anti-proliferative activity against cancer cell lines. However, the specific mechanism through which it exerts its anticancer effects remains unknown. Purpose: This study focused on elucidating the mechanism of action of dichapetalin M to further explore its potential as a therapeutic agent for resistant and metastatic breast cancer. Method: We confirmed the Estrogen Receptor (ER) as a target of Dic M, using an in vitro approach. Furthermore, we examined both the apoptotic and migrastatic effects of dichapetalin M by assessing its impact on the expression of key apoptosis-related and cancer cell migration genes. Finally, we evaluated the compound’s effect on Multi-drug Resistance Gene MDR1 expression, a gene linked to cancer drug resistance. Results: Our target validation experiments demonstrated that Dic M exhibited considerably higher cytotoxicity in ER-positive breast cell lines compared to ER-negative cell lines. Furthermore, treatment of MCF-7 cells (which are ER-positive) with Dic M led to a dose-dependent increase in the expression of AREG (amphiregulin) , a downstream effector of the Estrogen Receptor. Additionally, Dic M inhibited actin polymerization and significantly downregulated genes involved in the turnover of actin monomers. Scratch-wound assay results further demonstrate that Dic M reduces the rate of cell migration, although its impact on EMT-related gene expression was only observed at high doses. Additionally, Dic M treatment in MCF-7 cells resulted in a significant decrease in the expression of pro-apoptotic genes and MDR1 expression. Conclusions: These findings indicate that Dic M likely interacts with the Estrogen Receptor and employs the apoptotic pathway to exert its cytotoxic and anti-proliferative effects. Dic M exhibits promising potential, such as anti-migrastatic properties and downregulation of a key breast cancer resistance gene, warranting further investigation.
Open AccessTherapeutic Potential of Dichapetalin M in Metastatic and ER-positive Breast Cancer: Evidence from Cell Line Studies
Background: Dichapetalin M (Dic M), an active compound extracted from medicinal plants in the Dichapetalum genus, has been previously shown to possess anti-proliferative activity against cancer cell lines. However, the specific mechanism through which it exerts its anticancer effects remains unknown. Purpose: This study focused on elucidating the mechanism of action of dichapetalin M to further explore its potential as a therapeutic agent for resistant and metastatic breast cancer. Method: We confirmed the Estrogen Receptor (ER) as a target of Dic M, using an in vitro approach. Furthermore, we examined both the apoptotic and migrastatic effects of dichapetalin M by assessing its impact on the expression of key apoptosis-related and cancer cell migration genes. Finally, we evaluated the compound’s effect on Multi-drug Resistance Gene MDR1 expression, a gene linked to cancer drug resistance. Results: Our target validation experiments demonstrated that Dic M exhibited considerably higher cytotoxicity in ER-positive breast cell lines compared to ER-negative cell lines. Furthermore, treatment of MCF-7 cells (which are ER-positive) with Dic M led to a dose-dependent increase in the expression of AREG (amphiregulin) , a downstream effector of the Estrogen Receptor. Additionally, Dic M inhibited actin polymerization and significantly downregulated genes involved in the turnover of actin monomers. Scratch-wound assay results further demonstrate that Dic M reduces the rate of cell migration, although its impact on EMT-related gene expression was only observed at high doses. Additionally, Dic M treatment in MCF-7 cells resulted in a significant decrease in the expression of pro-apoptotic genes and MDR1 expression. Conclusions: These findings indicate that Dic M likely interacts with the Estrogen Receptor and employs the apoptotic pathway to exert its cytotoxic and anti-proliferative effects. Dic M exhibits promising potential, such as anti-migrastatic properties and downregulation of a key breast cancer resistance gene, warranting further investigation.
- Open Access
- 1 April 2025
- Published by Wolters Kluwer Health in Biomedical and Biotechnology Research Journal
- Vol. 9 (2) , 132-141
In vitro Antiparasitic and Anti-severe Acute Respiratory Syndrome Coronavirus 2 Activities of Extracts and Fractions from Pouteria alnifolia
Background: Although there is widespread use of herbal medicine in many parts of the world including tropical Africa, scientific evidence to validate efficacy and safety is largely scarce. The aim of this study was to investigate the potential of Pouteria alnifolia as an alternative anti-infective. Methods: In this study, bioactivity-guided isolation of extracts from different parts of P. alnifolia was done, and the in vitro antitrypanosomal, antileishmanial, anti-severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and cytotoxicity properties of the extracts and fractions were determined using the alamarBlue assay. Using microscopy, the growth kinetics of Trypanosoma brucei brucei was investigated by counting cells when parasites were exposed to different concentrations of selected extracts and fractions. Results: The results show that while anthracene and anthraquinone derivatives were absent in all the tested fractions, terpenoids, and cardiac glycosides were the most common phytochemicals in the fractions. Alkaloids were also detected in the dichloromethane (DCM) extracts of seeds and whole fruit (WF) compared to butanol (BuOH) fractions of the fruit pulp, stem, and roots. The IC 50 values for T. b. brucei were between 07 ± 0.0 and 59.5 ± 0.3 µg/mL while that of Leishmania donovani ranged from 1.3 ± 0.1 to 27.8 ± 1.8 µg/mL. DCM extracts from WF, seeds, and stem inhibited the growth of T. b. brucei , whereas the BuOH fractions from seeds and WFs were most active against SARS-CoV-2. Conclusion: Extracts and fractions from P. alnifolia appear to have useful chemotherapeutic agents that warrant further study for a variety of infections faced by those in tropical Africa.
- 1 April 2025
- Published by Wolters Kluwer Health in Biomedical and Biotechnology Research Journal
- Vol. 9 (2) , 132-141
Open AccessIn vitro Antiparasitic and Anti-severe Acute Respiratory Syndrome Coronavirus 2 Activities of Extracts and Fractions from Pouteria alnifolia
Background: Although there is widespread use of herbal medicine in many parts of the world including tropical Africa, scientific evidence to validate efficacy and safety is largely scarce. The aim of this study was to investigate the potential of Pouteria alnifolia as an alternative anti-infective. Methods: In this study, bioactivity-guided isolation of extracts from different parts of P. alnifolia was done, and the in vitro antitrypanosomal, antileishmanial, anti-severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and cytotoxicity properties of the extracts and fractions were determined using the alamarBlue assay. Using microscopy, the growth kinetics of Trypanosoma brucei brucei was investigated by counting cells when parasites were exposed to different concentrations of selected extracts and fractions. Results: The results show that while anthracene and anthraquinone derivatives were absent in all the tested fractions, terpenoids, and cardiac glycosides were the most common phytochemicals in the fractions. Alkaloids were also detected in the dichloromethane (DCM) extracts of seeds and whole fruit (WF) compared to butanol (BuOH) fractions of the fruit pulp, stem, and roots. The IC 50 values for T. b. brucei were between 07 ± 0.0 and 59.5 ± 0.3 µg/mL while that of Leishmania donovani ranged from 1.3 ± 0.1 to 27.8 ± 1.8 µg/mL. DCM extracts from WF, seeds, and stem inhibited the growth of T. b. brucei , whereas the BuOH fractions from seeds and WFs were most active against SARS-CoV-2. Conclusion: Extracts and fractions from P. alnifolia appear to have useful chemotherapeutic agents that warrant further study for a variety of infections faced by those in tropical Africa.
- 4 July 2024
- Published by Royal Society of Chemistry (RSC) in Natural Product Reports
- Vol. 41 (10) , 1579-1603
The dichapetalins and dichapetalin-type compounds: structural diversity, bioactivity, and future research perspectives
This review discusses the structural diversity of the dichapetalins and related compounds from the genera Dichapetalum and Phyllanthus, their manifestation in the diversity of their biological activities, and areas of potential future research.
- 4 July 2024
- Published by Royal Society of Chemistry (RSC) in Natural Product Reports
- Vol. 41 (10) , 1579-1603
The dichapetalins and dichapetalin-type compounds: structural diversity, bioactivity, and future research perspectives
This review discusses the structural diversity of the dichapetalins and related compounds from the genera Dichapetalum and Phyllanthus, their manifestation in the diversity of their biological activities, and areas of potential future research.
- Open Access
- 1 April 2024
- Published by Wolters Kluwer Health in Biomedical and Biotechnology Research Journal
- Vol. 8 (2) , 172-180
Evaluation of the Antitrypanosomal Activity of the Crude Extracts of Uvaria Ovata: In vitro and In silico Approach
Background: Human African trypanosomiasis is the third disease with most mortalities among the neglected tropical diseases. The absence of vaccines and the development of parasite resistance have necessitated the quest for new affordable and safe treatment options for the disease. This study aims to assess the potential ofUvaria ovataas an alternative new and safer antitrypanosomal therapeutics.Methods: Antitrypanosomal efficacies of extracts and fractions ofU. ovatawere determined by the Alamar Blue cell viability assay againstTrypanosoma brucei bruceiGUTat 3.1. Molecular docking was used to suggest the mechanism of action of the extracts and fractions by docking the curated compounds present in the plant against farnesyl diphosphate synthase (FPPS) and ornithine decarboxylase (ODC) enzymes.Results: Antitrypanosomal activities (IC50, μg/mL) obtained were within the range of 0.12–4.40, exceeding that of the standard suramin (4.96). A total of 17 known compounds fromU. ovatathat did not violate Lipinski’s rule of five with negligible toxicity produced molecular docking results against FPPS and ODC enzymes. Within the FPPS interaction landscape, mannosamine emerged as the most promising lead, with a binding energy of −6.4 kcal/mol and a predicted Ki value of 20.12 μM. With respect to ODC, 15 compounds exhibited binding affinities ranging from −4.6 to −6.3 kcal/mol, exceeding that of the known inhibitor allicin (−4.5 kcal/mol).Conclusion: This is the first report of the antitrypanosomal activity and mode of action suggestion ofU. ovata. The study sets the foundation for further exploration and validation of the therapeutic prospect ofU. ovatain the fight against trypanosomiasis.
- 1 April 2024
- Published by Wolters Kluwer Health in Biomedical and Biotechnology Research Journal
- Vol. 8 (2) , 172-180
Open AccessEvaluation of the Antitrypanosomal Activity of the Crude Extracts of Uvaria Ovata: In vitro and In silico Approach
Background: Human African trypanosomiasis is the third disease with most mortalities among the neglected tropical diseases. The absence of vaccines and the development of parasite resistance have necessitated the quest for new affordable and safe treatment options for the disease. This study aims to assess the potential ofUvaria ovataas an alternative new and safer antitrypanosomal therapeutics.Methods: Antitrypanosomal efficacies of extracts and fractions ofU. ovatawere determined by the Alamar Blue cell viability assay againstTrypanosoma brucei bruceiGUTat 3.1. Molecular docking was used to suggest the mechanism of action of the extracts and fractions by docking the curated compounds present in the plant against farnesyl diphosphate synthase (FPPS) and ornithine decarboxylase (ODC) enzymes.Results: Antitrypanosomal activities (IC50, μg/mL) obtained were within the range of 0.12–4.40, exceeding that of the standard suramin (4.96). A total of 17 known compounds fromU. ovatathat did not violate Lipinski’s rule of five with negligible toxicity produced molecular docking results against FPPS and ODC enzymes. Within the FPPS interaction landscape, mannosamine emerged as the most promising lead, with a binding energy of −6.4 kcal/mol and a predicted Ki value of 20.12 μM. With respect to ODC, 15 compounds exhibited binding affinities ranging from −4.6 to −6.3 kcal/mol, exceeding that of the known inhibitor allicin (−4.5 kcal/mol).Conclusion: This is the first report of the antitrypanosomal activity and mode of action suggestion ofU. ovata. The study sets the foundation for further exploration and validation of the therapeutic prospect ofU. ovatain the fight against trypanosomiasis.
- Open Access
- 19 July 2021
- Published by Wiley in Evidence-Based Complementary and Alternative Medicine
- Vol. 2021, 1-11
Antiproliferative Activities of Methanolic Extract and Fractions of Tetrapleura Tetraptera Fruit
Most of the current cancer chemotherapeutics are associated with harsh and undesirable side effects, including toxicity and chemoresistance, driving the need for safer and more effective alternatives. In this study, the antiproliferative activities of the methanolic extract of Tetrapleura tetraptera fruits and nine different fractions (C1C9) from the column chromatographic separation of the extract against leukemia (Jurkat) and human breast cancer (MCF-7) cell lines were investigated using a tetrazolium-based colorimetric assay. Phytochemical screening of the extract and fractions found alkaloids, carbohydrates, flavonoids, glycosides, phenols, saponins, steroids, tannins, and terpenoids in the methanolic extract. Most of the fractions exhibited antiproliferative activity (>100μg/mL) with the Jurkat cells being more susceptible than the MCF-7 cells. Four of the collected fractions C4, C3, C5, and C2 had good selective indices in decreasing order of activity, in the case of Jurkat cells. Liquid chromatography-mass spectrometry analysis of all samples (except for C4 and C9) revealed that C1, C2, C3, and C5 each had a single component. More importantly, fractions C2, C3, and C5, which were selective to Jurkat cells, also had the same retention time of 1.846min. Fractions C6 and C8 had two components, with C7 having four components. This study serves as a basis for further work to isolate and characterize potential anticancer agents from the fractions of extracts of T. tetraptera fruits.
- 19 July 2021
- Published by Wiley in Evidence-Based Complementary and Alternative Medicine
- Vol. 2021, 1-11
Open AccessAntiproliferative Activities of Methanolic Extract and Fractions of Tetrapleura Tetraptera Fruit
Most of the current cancer chemotherapeutics are associated with harsh and undesirable side effects, including toxicity and chemoresistance, driving the need for safer and more effective alternatives. In this study, the antiproliferative activities of the methanolic extract of Tetrapleura tetraptera fruits and nine different fractions (C1C9) from the column chromatographic separation of the extract against leukemia (Jurkat) and human breast cancer (MCF-7) cell lines were investigated using a tetrazolium-based colorimetric assay. Phytochemical screening of the extract and fractions found alkaloids, carbohydrates, flavonoids, glycosides, phenols, saponins, steroids, tannins, and terpenoids in the methanolic extract. Most of the fractions exhibited antiproliferative activity (>100μg/mL) with the Jurkat cells being more susceptible than the MCF-7 cells. Four of the collected fractions C4, C3, C5, and C2 had good selective indices in decreasing order of activity, in the case of Jurkat cells. Liquid chromatography-mass spectrometry analysis of all samples (except for C4 and C9) revealed that C1, C2, C3, and C5 each had a single component. More importantly, fractions C2, C3, and C5, which were selective to Jurkat cells, also had the same retention time of 1.846min. Fractions C6 and C8 had two components, with C7 having four components. This study serves as a basis for further work to isolate and characterize potential anticancer agents from the fractions of extracts of T. tetraptera fruits.
- Open Access
Constituents of the Roots of Dichapetalum pallidum and Their Anti-Proliferative Activity
As part of our search for bioactive compounds from the Dichapetalaceae, repeated chromatographic purification of the roots of a hitherto unexamined species, Dichapetalum pallidum, led to the isolation of the newly occurring 7-hydroxydichapetalin P (1) and the known dichapetalins A (2) and X (3). Also isolated were the known compounds friedelin-2,3-lactone (4), friedelan-3-one (6), friedelan-3β-ol (7) and pomolic (8), as well as the dipeptide aurantiamide acetate (5). The compounds were characterized by direct interpretation of their IR, 1D NMR and 2D NMR spectral data and by comparison of their physico-chemical data, including their chromatographic profiles, with the literature and authentic samples in our compound library for the genus Dichapetalum. The compounds were assayed for their anti-proliferative activities against the human T-lymphocytic leukemia (Jurkat), acute promyelocytic leukemia (HL-60) and T-lymphoblast-like leukemia (CEM) cell lines. Overall, dichapetalin X showed the strongest (3.14 μM) and broadest cytotoxic activities against all the leukemic cell lines tested, exhibiting even stronger activities than the standard compound, curcumin.
Open AccessConstituents of the Roots of Dichapetalum pallidum and Their Anti-Proliferative Activity
As part of our search for bioactive compounds from the Dichapetalaceae, repeated chromatographic purification of the roots of a hitherto unexamined species, Dichapetalum pallidum, led to the isolation of the newly occurring 7-hydroxydichapetalin P (1) and the known dichapetalins A (2) and X (3). Also isolated were the known compounds friedelin-2,3-lactone (4), friedelan-3-one (6), friedelan-3β-ol (7) and pomolic (8), as well as the dipeptide aurantiamide acetate (5). The compounds were characterized by direct interpretation of their IR, 1D NMR and 2D NMR spectral data and by comparison of their physico-chemical data, including their chromatographic profiles, with the literature and authentic samples in our compound library for the genus Dichapetalum. The compounds were assayed for their anti-proliferative activities against the human T-lymphocytic leukemia (Jurkat), acute promyelocytic leukemia (HL-60) and T-lymphoblast-like leukemia (CEM) cell lines. Overall, dichapetalin X showed the strongest (3.14 μM) and broadest cytotoxic activities against all the leukemic cell lines tested, exhibiting even stronger activities than the standard compound, curcumin.